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Additional data of diagnostic, prognostic, and therapeutic signifi-
cance may be obtained by serial SAA measurements. For routine use,
serial measurements of CRP levels seem to form a suitable alterna-
tive.
7.2. SUMMARY
Amyloidosis is a disease characterized by organ function distur-
bances, caused by the extracellular deposition of protein fibrils. The
molecular structure of these fibrils (beta-pleated sheet structure) is
responsible for the failure of the human organism to rid itself from
amyloid, once it has been deposited. In addition this molecular struc-
ture is held responsible for the binding of the dye Congo red and the
consequent green birefringence with polarized light, a property by
which amyloid is defined histologically.
In human pathology several types of amyloidosis can be discerned,
among which different forms of familial and non-familial systemic
amyloidosis , and a number of localized forms. Although in all these
types of amyloidosis the amyloid fibrils display the same molecular
structure, considerable differences have been demonstrated in the
primary structure (i.e. the sequence of amino acids constituting the
protein), which appear to be related to differences in the clinical pre-
sentation of amyloidosis.
The types of amyloidosis which are of major importance in clinical
medicine, are systemic AL amyloidosis and systemic AA amyloidosis.
The designations AL and AA refer to the major protein component
of the fibrils in these types of amyloidosis (Chapter 2.2. and 2.3.).
Protein AL is derived from immunoglobulin light chains, whereas
protein AA is derived from an immunochemically relared acute-
phase protein, which has been designated SAA.
The characteristics of protein AL and protein AA indicated above,
may explain why AL amyloidosis is associated with an aberrant pro-
duction of immunoglobulin light chains, and why AA amyloidosis is
associated with chronic inflammatory diseases or other disease states
which are accompanied by an acute-phase response.
In our study we describe a modified clinical classification of amy-
loidosis, based upon differences in the pattern of organ disfunction
(Chapter 5.1.). This clinical classification is compared with the results
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of a simple histochemical method to differentiare between AA
amyloid and other types of amyloid (Chapter 5.2.). Using the combi-
nation of clinical, laboratory, and histochemical data, it appears to be
possible to identify systemic AA and systemic AL amyloidosis. Subse-
quently a comparison is made between the SAA levels in patients
with systemic AA and systemic AL amyloidosis (Chapter 5.3.). As had
already been expected on theoretical grounds, the development of
systemic AL amyloidosis is not dependent on elevated SAA levels. In
systemic AA amyloidosis however, SAA levels show a clear correla-
tion with the progression of amyloidosis in terms of organ disfunc-
tion. The major organ disfunction in AA amyloidosis being nephro-
pathy, patients with highly elevated SAA levels tended to end up with
renal failure, whereas renal function remained stationary in patients,
who had only moderately elevated or normal SAA levels at the time
of diagnosis.
In Chapter 6 the consequences of these studies in terms of treat-
ment are discussed, and illustrated by the case histories of 7 patients
with systemic AA amyloidosis associated with rheumatoid arthritis.
It seems possible to stop the progression of AA amyloidosis by redu-
cing the SAA levels, using drugs which are able to suppress the in-
flammatory activity. Monitoring of the SAA levels provides the pos-
sibility to establish, wether such a treatment is indicated and to adjust
the dosage of the drug to the need of the individual patient.
Another acute-phase protein, which displays kinetics similar to
that of SAA, is C-reactive protein (CRP). Comparison of SAA and
CRP levels demonstrates that the measurement of CRP levels by
radial immunodiffusion, provides a suitable alternative for routine
clinical use.
The characterization of two AA proteins (Chapter 4.1.), necessary
for the establishment of a radioimmunoassay for SAA, yielded inte-
resting data which contribute to the insight inro the pathogenesis of
AA amyloidosis.
The radioimmunoassay itself appears to have several advantages
over the other assays described sofar. The correlation of the SAA
levels with the inflammatory activiry in patients with polyarthritis,
evoked new questions about the basic mechanisms of inflammation,
which have become subiect of further research.
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